CPAI - ETF AI Analysis
Top Page
Counterpoint Quantitative Equity ETF (CPAI)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and in recent months, showing solid momentum.
Growth-Oriented Technology Exposure
Nearly half of the fund is invested in technology companies, many of which have shown strong year-to-date performance and are helping drive returns.
Healthy Asset Base
With hundreds of millions in assets under management, the fund is large enough to offer reasonable trading liquidity for most individual investors.
Negative Factors
High Expense Ratio
The fund charges relatively high fees for an ETF, which can eat into long-term returns compared with lower-cost alternatives.
Heavy Concentration in Technology
A large tilt toward the technology sector increases the fund’s sensitivity to downturns in that single area of the market.
Very Limited Geographic Diversification
Almost all holdings are in U.S. companies, so the fund offers little protection if the U.S. market struggles compared with other regions.
CPAI vs. SPDR S&P 500 ETF (SPY)
AUM282.45M
RegionNorth America
Expense Ratio0.75%
Beta1.08
IssuerCounterpoint
Inception DateNov 28, 2023
Dividend Yield0.76%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume39,027
30 Day Avg. Volume44,483
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
59.28Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CPAI Summary
The Counterpoint Quantitative Equity ETF (CPAI) is a U.S. stock fund that uses a data-driven strategy instead of tracking a set index. It aims to cover the whole U.S. market, mixing different sizes and styles of companies, with a big tilt toward technology and health care. Well-known holdings include Micron and Teradyne. Someone might invest in CPAI to get broad, one-stop stock market exposure with a focus on growth opportunities. A key risk is that it is heavily invested in tech stocks, so its price can swing a lot when that sector rises or falls.
How much will it cost me?The Counterpoint Quantitative Equity ETF (CPAI) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, using a quantitative approach to select stocks rather than simply tracking an index.
What would affect this ETF?The Counterpoint Quantitative Equity ETF (CPAI), with its focus on the U.S. market and diverse sector exposure, could benefit from strong growth in technology and healthcare sectors, driven by innovation and increased demand. However, it may face challenges from rising interest rates or economic slowdowns, which could negatively impact consumer spending and cyclical industries. Regulatory changes or geopolitical tensions affecting North America could also influence the ETF's performance.
CPAI Top 10 Holdings
CPAI’s story is all about punchy U.S. tech bets driving the show. High-flyers like Credo Technology and Viavi Solutions have been rising sharply, giving the fund a strong tailwind, while Micron and Teradyne add steadier, AI-linked momentum rather than fireworks. On the flip side, names like RealReal and Centene are lagging, quietly tugging at returns and reminding investors this isn’t a one-way ride. With a heavy tilt toward smaller, fast-moving tech and related plays, the ETF is firmly U.S.-focused and more concentrated in growthy names than a typical broad market fund.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Credo Technology Group Holding Ltd | 3.40% | $9.46M | $36.57B | 309.44% | 77 Outperform | |
| Astera Labs, Inc. | 3.20% | $8.89M | $36.41B | 200.90% | 68 Neutral | |
| Micron | 3.01% | $8.35M | $751.74B | 706.81% | 79 Outperform | |
| Centene | 2.89% | $8.02M | $27.32B | -12.06% | 58 Neutral | |
| Viavi Solutions | 2.78% | $7.72M | $12.40B | 488.24% | 71 Outperform | |
| RealReal | 2.52% | $7.00M | $1.57B | 84.40% | 54 Neutral | |
| Alphabet Class A | 2.33% | $6.48M | $4.81T | 162.94% | 85 Outperform | |
| EZCORP | 2.29% | $6.35M | $2.06B | 128.10% | 75 Outperform | |
| Tenable Holdings | 2.18% | $6.06M | $2.33B | -32.40% | 61 Neutral | |
| Lightpath Technologies | 2.17% | $6.03M | $742.71M | 447.66% | 53 Neutral |
CPAI Technical Analysis
Positive
―
Price Trends
44.09
Positive
43.34
Positive
40.67
Positive
Market Momentum
1.03
Negative
63.03
Neutral
87.68
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CPAI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 46.16, equal to the 50-day MA of 44.09, and equal to the 200-day MA of 40.67, indicating a bullish trend. The MACD of 1.03 indicates Negative momentum. The RSI at 63.03 is Neutral, neither overbought nor oversold. The STOCH value of 87.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CPAI.
CPAI Peer Comparison
Comparison Results
Performance Comparison
CPAI
Counterpoint Quantitative Equity ETF
47.16
13.52
40.19%
SYLD
Cambria Shareholder Yield ETF
―
―
―
ULTY
YieldMax Ultra Option Income Strategy ETF
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
AVTM
Avantis Total Equity Markets ETF
―
―
―
XCHG
AB US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents